Bioactive lipid mediators in plasma are predictors of preeclampsia irrespective of aspirin therapy.

Autor:	Stephenson DJ; Division of Hematology & Oncology, Department of Medicine, University of Virginia, Charlottesville, VA, USA., MacKnight HP; Division of Hematology & Oncology, Department of Medicine, University of Virginia, Charlottesville, VA, USA., Hoeferlin LA; Department of Biochemistry and Molecular Biology, Virginia Commonwealth University (VCU), Richmond, VA, USA., Washington SL; Department of Obstetrics and Gynecology, Virginia Commonwealth University, Richmond, VA, USA., Sawyers C; Virginia Institute for Psychiatric & Behavioral Genetics, Virginia Commonwealth University School of Medicine, Richmond, VA, USA., Archer KJ; Division of Biostatistics, The Ohio State University College of Public Health, Columbus, OH, USA., Strauss JF 3rd; Department of Obstetrics and Gynecology, Virginia Commonwealth University, Richmond, VA, USA., Walsh SW; Department of Obstetrics and Gynecology, Virginia Commonwealth University, Richmond, VA, USA. Electronic address: Scott.Walsh@vcuhealth.org., Chalfant CE; Division of Hematology & Oncology, Department of Medicine, University of Virginia, Charlottesville, VA, USA; Department of Biochemistry and Molecular Biology, Virginia Commonwealth University (VCU), Richmond, VA, USA; Department of Cell Biology, University of Virginia, Charlottesville, VA, USA; Program in Cancer Biology, University of Virginia Cancer Center, Charlottesville, VA, USA; Research Service, Richmond Veterans Administration Medical Center, Richmond, VA, USA. Electronic address: cechalfant@virginia.edu.
Jazyk:	angličtina
Zdroj:	Journal of lipid research [J Lipid Res] 2023 Jun; Vol. 64 (6), pp. 100377. Date of Electronic Publication: 2023 Apr 27.
DOI:	10.1016/j.jlr.2023.100377
Abstrakt:	There are few early biomarkers to identify pregnancies at risk of preeclampsia (PE) and abnormal placental function. In this cross-sectional study, we utilized targeted ultra-performance liquid chromatography-ESI MS/MS and a linear regression model to identify specific bioactive lipids that serve as early predictors of PE. Plasma samples were collected from 57 pregnant women prior to 24-weeks of gestation with outcomes of either PE (n = 26) or uncomplicated term pregnancies (n = 31), and the profiles of eicosanoids and sphingolipids were evaluated. Significant differences were revealed in the eicosanoid, (±)11,12 DHET, as well as multiple classes of sphingolipids; ceramides, ceramide-1-phosphate, sphingomyelin, and monohexosylceramides; all of which were associated with the subsequent development of PE regardless of aspirin therapy. Profiles of these bioactive lipids were found to vary based on self-designated race. Additional analyses demonstrated that PE patients can be stratified based on the lipid profile as to PE with a preterm birth linked to significant differences in the levels of 12-HETE, 15-HETE, and resolvin D1. Furthermore, subjects referred to a high-risk OB/GYN clinic had higher levels of 20-HETE, arachidonic acid, and Resolvin D1 versus subjects recruited from a routine, general OB/GYN clinic. Overall, this study shows that quantitative changes in plasma bioactive lipids detected by ultra-performance liquid chromatography-ESI-MS/MS can serve as an early predictor of PE and stratify pregnant people for PE type and risk. Competing Interests: Conflict of interest All authors of this article declare that they have no competing financial interests. (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz: